SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

AimedBio’s BI 4060107 Begins Phase 1 Trial Dosing

The first patient has been dosed in the Phase 1 trial of BI 4060107, an antibody-drug conjugate discovered by AimedBio and being developed by Boehringer Ingelheim.

Related stories